Bausch Health Companies Inc. announced that both global Phase 3 RED-C trials evaluating amorphous-rifaximin solid soluble dispersion (SSD) for the prevention of hepatic encephalopathy in cirrhosis patients failed to meet their primary endpoints. The studies, which enrolled over 1,000 patients across 17 countries, showed that rifaximin SSD was safe and well-tolerated but did not demonstrate statistically significant efficacy in delaying the first episode of hepatic encephalopathy.

What this trial failure reveals about rifaximin SSD’s clinical limitations in cirrhosis prevention

While rifaximin is already a mainstay in secondary prevention of hepatic encephalopathy, the RED-C program represented a major test of its potential to move upstream into primary prevention. The amorphous SSD formulation was designed to enhance bioavailability and pharmacokinetic performance, and the program marked one of the most ambitious late-stage efforts to delay the onset of hepatic encephalopathy in cirrhosis patients without prior episodes.

By failing to meet its primary endpoint, the RED-C outcome underscores the biological and methodological challenges in this patient subset. Clinicians tracking the field have long debated whether primary prevention trials in hepatic encephalopathy can produce clear outcomes, given the heterogeneity of liver function, confounding comorbidities, and the subjective nature of early neurological symptoms.

The RED-C results suggest that even pharmacologically active agents like rifaximin may struggle to provide measurable benefit when deployed in a preventive context, especially where progression risk is more stochastic and multifactorial than in post-episode recurrence scenarios.

Why the hepatology field still lacks a regulatory anchor for primary prevention in hepatic encephalopathy

Regulatory watchers note that there is currently no approved treatment for the primary prevention of hepatic encephalopathy in patients with cirrhosis. This gap has persisted despite cirrhosis being a major public health burden, with hepatic encephalopathy often serving as the first clinical decompensation event that signals worsening prognosis.

The RED-C program was widely viewed as a potential precedent-setter. Its failure will likely delay the creation of any regulatory framework around primary prophylaxis in this indication. Without a successful trial to anchor endpoints and patient selection strategies, drug developers may hesitate to pursue similar programs.

Additionally, the FDA’s and EMA’s evolving positions on trial enrichment, real-world relevance, and surrogate markers in liver disease will come under renewed scrutiny as the field reconsiders what a feasible trial design looks like for this patient group.

Trial design scrutiny likely to follow given RED-C’s ambitious scope and global enrolment

RED-C’s design, involving over 1,000 patients across 398 sites in 17 countries, reflects the scale required to power a trial for an episodic and variable outcome like hepatic encephalopathy onset. But industry observers note that such expansive geographies introduce operational inconsistencies, variable diagnostic practices, and site-level heterogeneity that can dilute signal detection.

Moreover, while RED-C was double-blind and placebo-controlled, critics may question whether its endpoints adequately captured early neurocognitive impairment or subtle shifts in hepatic function that precede overt encephalopathy. The timing of first-episode onset is often influenced by factors outside drug intervention, including infections, bleeding, electrolyte shifts, and patient adherence.

This raises important considerations for future trial designs—particularly whether composite or biomarker-anchored endpoints could provide a more objective framework for prevention studies.

Strategic recalibration expected as Bausch evaluates next steps for rifaximin SSD

Executives at Bausch Health have signaled their intent to review the full dataset to determine possible future development paths for rifaximin SSD. However, the failed RED-C trials will significantly narrow strategic optionality.

Unless a subset analysis reveals a high-risk population or secondary endpoints with promising trends, the pathway to repurposing rifaximin SSD may be commercially and scientifically constrained. Analysts suggest that future use cases may pivot toward non-cirrhotic applications or adjunctive roles in broader hepatic or gastrointestinal indications.

This setback also adds pressure on Bausch Health to sharpen its pipeline prioritization within hepatology, where marketable innovation has historically been difficult to achieve without strong surrogate endpoints or a well-established clinical precedent.

Investors likely to monitor whether RED-C fallout affects broader capital allocation or partner interest

While Bausch Health had not explicitly pegged rifaximin SSD to near-term revenue forecasts, the RED-C program had been viewed as a potential differentiator within its gastroenterology and hepatology portfolio. Its failure could impact investor perception of the company’s R&D strategy and raise questions about the capital efficiency of large-scale global trials without robust Phase 2 signals.

If the RED-C data yield no viable signals for continued development, investors may expect a tighter capital allocation approach in future programs, particularly those attempting to break new regulatory ground without clearly defined endpoints. Potential licensing or co-development interest in rifaximin SSD may also wane absent a clear path forward.

Why hepatic encephalopathy still remains a stubborn frontier in liver disease treatment

Hepatic encephalopathy continues to resist simplification. Despite growing understanding of gut-liver-brain axis dynamics and the role of microbiome modulation, primary prevention remains elusive. The RED-C results remind stakeholders that even well-tolerated agents with proven efficacy in related contexts may not translate when the intervention window is too early, or the disease too multifactorial.

Clinicians familiar with cirrhosis management often note that patient behavior, dietary compliance, and precipitating complications may contribute more to encephalopathy onset than drug-modifiable pathways. This introduces a mismatch between drug mechanism and real-world risk drivers that trial design alone cannot solve.

The hepatology field will likely need not just better drugs but better models—both statistical and biological—to predict and preempt encephalopathy in early-stage cirrhosis. Until then, drug developers face high-risk, high-cost pathways with uncertain regulatory and commercial reward.

RED-C’s Phase 3 failure and the future of hepatic encephalopathy prevention

Bausch Health’s RED-C Phase 3 trial failure marks a significant setback in the pursuit of primary prevention for hepatic encephalopathy in cirrhosis patients. Despite a strong safety profile, rifaximin SSD did not demonstrate efficacy in delaying the first episode of encephalopathy. The implications go beyond the molecule, exposing systemic challenges in trial design, endpoint selection, and regulatory alignment for preventive strategies in liver disease. Unless further data offer salvageable insights, Bausch may be forced to reallocate pipeline resources. More broadly, the RED-C outcome could deter similar development efforts in this notoriously complex space, where clinical need remains acute but solutions continue to evade consensus.

  Bausch Health Companies Inc., gastroenterology, hepatic encephalopathy, hepatology, liver cirrhosis, Phase 3 trial, RED-C trial, rifaximin SSD